Verrica Pharmaceuticals Appoints Eugene Scavola to the Position of Executive Vice President, Technical Operations
October 09 2019 - 07:00AM
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a
medical dermatology company committed to the development and
commercialization of novel treatments that provide meaningful
benefit for people living with skin diseases, today announced it
has appointed Eugene Scavola to the role of Executive Vice
President, Technical Operations.
An accomplished life sciences industry veteran, Mr. Scavola will
spearhead Verrica’s Chemistry Manufacturing and Controls (CMC)
functions. In this capacity, he will lead operational and technical
aspects of product development, contract manufacturing, and
analytical development activities for all Verrica product
candidates.
“As we advance our lead product candidate, VP-102, CMC becomes
an increasingly critical aspect of our overall operations,” said
Ted White, President and Chief Executive Officer of Verrica. “We
are extremely pleased to have an industry leader like Eugene
Scavola overseeing a myriad of aspects of our product development
and contract manufacturing, and we are confident in his ability to
bring new innovations and increased efficiencies to our technical
operations.”
Mr. Scavola has more than 25 years of measurable successes
spearheading the establishment of supply chain infrastructure,
managing production processes, and overseeing various operational
functions across a broad range of consumer healthcare,
pharmaceutical, and biotechnology entities. Prior to joining
Verrica, Mr. Scavola was a Managing Partner at PBM Capital Group.
In this capacity, he led product development and supply chain
functions, as well as organizational restructuring and FDA
interactions for a wide range of life science portfolio companies
transitioning to standalone entities. In a previous role, Mr.
Scavola spent over 15 years, and held a number of leadership
positions, with Wyeth/Pfizer at several of its key sites. These
roles, of increasing and varying responsibilities, encompassed
manufacturing site operations, business systems development and
implementation, facilities infrastructure construction project
management, and key strategic operational project leadership.
During this time, Mr. Scavola was also responsible for the design
and implementation of several enterprise-wide manufacturing and
automation interface systems. In the role of Primary Processing
Unit Lead, he managed successful efforts to pass FDA biennial and
pre-approval inspections, as well as several international
regulatory agency inspections, with no critical observations. He
also was directly responsible for the successful launch of dozens
of consumer healthcare and pharmaceutical products, and management
of numerous operational efficiency and cost savings projects. Mr.
Scavola holds a Masters in Systems Engineering from the University
of Virginia, and a BS in Applied Economics from the Wharton School,
University of Pennsylvania.
About Verrica Pharmaceuticals Inc.
Verrica is a medical dermatology company committed to the
development and commercialization of novel treatments that provide
meaningful benefit for people living with skin diseases. The
Company’s late-stage product candidate, VP-102, is a potential
first-in-class topical therapy for the treatment of molluscum
contagiosum and common warts. Molluscum is a highly contagious
viral skin infection affecting approximately six million people,
primarily children, in the United States, and common warts are
contagious skin growths affecting 22 million people. There are
currently no FDA-approved treatments for molluscum or common
warts. Following positive topline results from two pivotal Phase 3
trials, the Company submitted an NDA in September 2019 for VP-102
for the treatment of molluscum. Verrica is planning to meet with
the FDA to determine next steps on the development of
VP-102 for common warts following positive Phase 2 results. VP-102
is also currently in a Phase 2 trial for the treatment of external
genital warts. A second product candidate, VP-103, is in
pre-clinical development for plantar warts. For more information,
visit www.verrica.com.
Forward-Looking Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
“believe,” “expect,” “may,” “plan,” “potential,” “will,” and
similar expressions, and are based on Verrica’s current beliefs and
expectations. These forward-looking statements include expectations
regarding the potential benefits of VP-102 for the treatment of
molluscum, the clinical development of VP-102 for additional
indications and the potential for new innovations and increased
efficiencies to Verrica’s technical operations. These statements
involve risks and uncertainties that could cause actual results to
differ materially from those reflected in such statements. Risks
and uncertainties that may cause actual results to differ
materially include uncertainties inherent in the drug development
process and the regulatory approval process, Verrica’s reliance on
third parties over which it may not always have full control, and
other risks and uncertainties that are described in Verrica’s
Annual Report on Form 10-K for the year ended December 31, 2018,
filed with the U.S. Securities and Exchange Commission on March 7,
2019, and other filings Verrica makes with the U.S. Securities and
Exchange Commission. Any forward-looking statements speak only as
of the date of this press release and are based on information
available to Verrica as of the date of this release, and Verrica
assumes no obligation to, and does not intend to, update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
Chris DegnanChief Financial
Officer484.453.3300 ext. 103info@verrica.com
Chiara RussoSolebury
Trout617.221.9197crusso@soleburytrout.com
Media:
Joshua R. MansbachSolebury
Trout646-378-2964jmansbach@troutgroup.com
Verrica Parmaceuticals (NASDAQ:VRCA)
Historical Stock Chart
From Mar 2024 to Mar 2024
Verrica Parmaceuticals (NASDAQ:VRCA)
Historical Stock Chart
From Mar 2023 to Mar 2024